BUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy

Reuters

Jun 17, 2025

BUZZ-Dyne <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls on revised timelines for genetic disorder therapy

** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20

** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA

** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting

** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo

** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously

** Also pushes submission seeking accelerated approval to late 2026 from H1 2026

** Stock down ~47% YTD

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544980979"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544980979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544980979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544980979","market":"fut","top_or_hot":-1,"title":"BUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> falls on revised timelines for genetic disorder therapy</title></head><body><p>** Shares of therapy developer Dyne Therapeutics <span>DYN.O</span> fall 19.03% to $11.20</p><p>** Co <span>revises</span> timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA</p><p>** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting</p><p>** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo</p><p>     ** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously</p><p>     ** Also pushes submission seeking accelerated approval to late 2026 from H1 2026 </p><p>** Stock down ~47% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p> ((Sriparna.Roy@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> falls on revised timelines for genetic disorder therapy</title></head><body><p>** Shares of therapy developer Dyne Therapeutics <span>DYN.O</span> fall 19.03% to $11.20</p><p>** Co <span>revises</span> timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA</p><p>** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting</p><p>** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo</p><p>     ** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously</p><p>     ** Also pushes submission seeking accelerated approval to late 2026 from H1 2026 </p><p>** Stock down ~47% YTD</p><p> (Reporting by Sriparna Roy in Bengaluru)</p><p> ((Sriparna.Roy@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nL4N3SK151:1","article_id":"2544980979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544980979","pubTimestamp":1750168340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo     ** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously     ** Also pushes submission seeking accelerated approval to late 2026 from H1 2026 ** Stock down ~47% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","DYN":"戴纳基","BK4139":"生物科技"},"translate_title":"BUZZ-Dyne Therapeutics修改了遗传疾病治疗时间表","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":0.9},"content_text":"BUZZ-Dyne Therapeutics falls on revised timelines for genetic disorder therapy** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo     ** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously     ** Also pushes submission seeking accelerated approval to late 2026 from H1 2026 ** Stock down ~47% YTD (Reporting by Sriparna Roy in Bengaluru) ((Sriparna.Roy@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}